These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 23513918)

  • 1. [Prediction of efficacy of molecular targeted agents for rheumatoid arthritis].
    Izumi K; Kameda H
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():658-63. PubMed ID: 23513918
    [No Abstract]   [Full Text] [Related]  

  • 2. TNF-alpha antagonists and other recombinant proteins for the treatment of rheumatoid arthritis.
    Brasington R
    J Hand Surg Am; 2009 Feb; 34(2):349-50. PubMed ID: 19135810
    [No Abstract]   [Full Text] [Related]  

  • 3. [Biological agents for therapy of rheumatoid arthritis--overview].
    Takeuchi T
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():513-6. PubMed ID: 15799409
    [No Abstract]   [Full Text] [Related]  

  • 4. Abatacept: new drug. Rheumatoid arthritis: after failure of TNF alpha antagonists and rituximab.
    Prescrire Int; 2008 Dec; 17(98):232. PubMed ID: 19422143
    [No Abstract]   [Full Text] [Related]  

  • 5. Rheumatoid arthritis: non-tumor necrosis factor targets.
    Pollard L; Choy E
    Curr Opin Rheumatol; 2005 May; 17(3):242-6. PubMed ID: 15838231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative overview of safety of the biologics in rheumatoid arthritis.
    Khraishi M
    J Rheumatol Suppl; 2009 Jun; 82():25-32. PubMed ID: 19509327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rheumatoid arthritis: beyond tumor necrosis factor-alpha antagonists, B cell depletion, and T cell blockade.
    Manadan AM; Block JA
    Am J Ther; 2008; 15(1):53-8. PubMed ID: 18223354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Rheumatoid arthritis].
    Tsukamoto M; Takeuchi T
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():534-8. PubMed ID: 23513897
    [No Abstract]   [Full Text] [Related]  

  • 9. Putting new disease-modifying antirheumatic drugs into perspective.
    Saseen JJ
    Pharmacotherapy; 2007 Dec; 27(12):1609-10. PubMed ID: 18041880
    [No Abstract]   [Full Text] [Related]  

  • 10. Do we need new treatment that goes beyond tumor necrosis factor blockers for rheumatoid arthritis?
    Voll RE; Kalden JR
    Ann N Y Acad Sci; 2005 Jun; 1051():799-810. PubMed ID: 16127017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
    Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C;
    Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists.
    Isaacs JD
    Expert Opin Biol Ther; 2009 Dec; 9(12):1463-75. PubMed ID: 19916731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Molecular targeting therapy in rheumatoid arthritis].
    Mima T; Nakashima Y; Hanba Y; Ohya M; Negi S; Shigematsu T
    Nihon Jinzo Gakkai Shi; 2012; 54(5):603-9. PubMed ID: 22991840
    [No Abstract]   [Full Text] [Related]  

  • 14. [TNF-alpha antibody in rheumatoid arthritis. Efficacy-risk relationship is positively evaluated].
    MMW Fortschr Med; 2002 May; 144(20):65. PubMed ID: 12119893
    [No Abstract]   [Full Text] [Related]  

  • 15. Tumor necrosis factor alpha haplotypes versus tumor necrosis factor alpha -308 G/A polymorphism in the prediction of infliximab treatment efficacy in rheumatoid arthritis.
    Mugnier B; Roudier J
    Arthritis Rheum; 2004 Dec; 50(12):4075-6; author reply 4076-7. PubMed ID: 15593229
    [No Abstract]   [Full Text] [Related]  

  • 16. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
    Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
    J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
    [No Abstract]   [Full Text] [Related]  

  • 17. Relative efficacies: antimalarials to abatacept - the choice is ours.
    Russell AS
    J Rheumatol Suppl; 2009 Jun; 82():17-24. PubMed ID: 19509326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should anti-tumor necrosis factor-alpha be the first therapy for rheumatoid vasculitis?
    Garcia-Porrua C; Gonzalez-Gay MA; Quevedo V
    J Rheumatol; 2006 Feb; 33(2):433; author reply 433-4. PubMed ID: 16465676
    [No Abstract]   [Full Text] [Related]  

  • 19. [MRA for therapy of rheumatoid arthritis].
    Nishimoto N; Mihara M
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():538-43. PubMed ID: 15799414
    [No Abstract]   [Full Text] [Related]  

  • 20. Biologic therapy for rheumatoid arthritis.
    Klippel JH
    N Engl J Med; 2000 Nov; 343(22):1640-1. PubMed ID: 11096174
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.